CNTB241220P2500
- 0.00
- 0.000.00%
Connect Biopharma Newsroom
Connect Biopharma Hldgs Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $8 Price Target
H.C. Wainwright Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $8
Optimistic Buy Rating for Connect Biopharma: Strategic Partnerships and Regulatory Progress Fuel Potential for Rademikibart
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $8 Price Target
Connect Biopharma Hldgs Analyst Ratings
HC Wainwright & Co. : The rating of Conrad Biopharmaceuticals (CNTB.US) was maintained, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $8.00.
Connect Biopharma Hldgs Analyst Ratings
HC Wainwright & Co. Maintains Buy on Connect Biopharma Hldgs, Raises Price Target to $8
Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)
Buy Rating Reaffirmed for Connect Biopharma Holdings Amid Promising Clinical Trials and Strategic Partnerships
Connect Biopharma Hldgs Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Connect Biopharma Holdings (CNTB) and Inspire Medical Systems (INSP)
Cantor Fitzgerald Reiterates Overweight on Connect Biopharma Hldgs, Maintains $5 Price Target
Connect Biopharma Hldgs Analyst Ratings
SVB Securities Remains a Buy on Connect Biopharma Holdings (CNTB)
SVB Securities Adjusts Connect Biopharma Price Target to $7 From $9, Maintains Outperform Rating
Connect Biopharma Hldgs Analyst Ratings